Invesaro

Stocks Comparison

P3 Health Partners vs GeneDx: revenue, profit, margins and growth compared

P3 Health Partners brought in $1.5B of revenue in fiscal 2024, GeneDx $427.5M in fiscal 2025. Revenue changed by -2.8% at P3 Health Partners and +40.0% at GeneDx on the year before, so GeneDx grew faster. P3 Health Partners kept -10.1% of its revenue as net profit, GeneDx -4.9%.

Side by side, latest fiscal year

PIIIWGS
Fiscal year endedFY2024 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.5B$427.5M
Revenue growth-2.8%+40.0%
Net income-$147.9M-$21M
Net margin-10.1%-4.9%
Free cash flown/a$14.3M
Free cash flow marginn/a3.3%
Earnings per share (diluted)-$45.26-$0.73
Cash$25M$105M
Debt$273.4M$54.5M
Price to earningsn/an/a
Market value$51.2M$2.6B
Dividend yieldn/an/a
Rank by revenue in sector#124 of 523 · Health care#199 of 523 · Health care

Over the years

Revenue
PIII FY2019: $145.5MPIII FY2021: $491.1MPIII FY2022: $1BPIII FY2023: $1.3BPIII FY2024: $1.5BPIII FY2024: $1.5BWGS FY2019: $196.2MWGS FY2020: $179.3MWGS FY2021: $212.2MWGS FY2022: $234.7MWGS FY2023: $202.6MWGS FY2024: $305.5MWGS FY2025: $427.5MFY19FY20FY21FY22FY23FY24FY25
PIII $1.5BWGS $427.5M
Net income
PIII FY2019: -$42MPIII FY2021: -$31.4MPIII FY2022: -$270.1MPIII FY2023: -$57.8MPIII FY2024: -$135.8MPIII FY2024: -$147.9MWGS FY2019: -$29.7MWGS FY2020: -$241.3MWGS FY2021: -$245.4MWGS FY2022: -$549MWGS FY2023: -$175.8MWGS FY2024: -$52.3MWGS FY2025: -$21MFY19FY20FY21FY22FY23FY24FY25
PIII -$147.9MWGS -$21M
Net margin
PIII FY2019: -28.8%PIII FY2021: -6.4%PIII FY2022: -25.7%PIII FY2023: -4.6%PIII FY2024: -9.1%PIII FY2024: -10.1%WGS FY2019: -15.1%WGS FY2020: -134.6%WGS FY2021: -115.6%WGS FY2022: -233.9%WGS FY2023: -86.8%WGS FY2024: -17.1%WGS FY2025: -4.9%FY19FY20FY21FY22FY23FY24FY25
PIII -10.1%WGS -4.9%
Revenue growth
PIII FY2021: +237.5%PIII FY2023: +20.7%PIII FY2024: +18.5%PIII FY2024: -2.8%WGS FY2020: -8.6%WGS FY2021: +18.3%WGS FY2022: +10.6%WGS FY2023: -13.7%WGS FY2024: +50.8%WGS FY2025: +40.0%FY20FY21FY22FY23FY24FY25
PIII -2.8%WGS +40.0%
Free cash flow
PIII FY2019: -$29.7MPIII FY2021: -$27.5MPIII FY2022: -$128.3MPIII FY2023: -$77.9MPIII FY2024: -$110.1MWGS FY2019: -$30.7MWGS FY2020: -$117.2MWGS FY2021: -$199.8MWGS FY2022: -$326.3MWGS FY2023: -$185.4MWGS FY2024: -$34MWGS FY2025: $14.3MFY19FY20FY21FY22FY23FY24FY25
PIII -$110.1MWGS $14.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about P3 Health Partners and GeneDx

Which is bigger by revenue, P3 Health Partners or GeneDx?

P3 Health Partners is bigger by revenue: $1.5B in fiscal 2024, against $427.5M for GeneDx in fiscal 2025.

Which keeps more of its revenue as profit, P3 Health Partners or GeneDx?

P3 Health Partners had a net margin of -10.1% in fiscal 2024; GeneDx had -4.9% in fiscal 2025.

Which grew revenue faster, P3 Health Partners or GeneDx?

In their latest fiscal years revenue changed by -2.8% at P3 Health Partners and +40.0% at GeneDx.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies